Abstract | BACKGROUND: METHODS: RESULTS: Immunohistochemical analysis revealed 62% of patients (27 primary and 5 recurrent) were thyroid-stimulating hormone receptor membranous immunostain positive. In vitro uptake of 1nM [89Zr]Zr-TR1402 was 38 ± 17% bound/mg in thyroid-stimulating hormone receptor-positive THJ529T thyroid cancer cell lines compared to 3.2 ± 0.5 in the low-expressing cell line (P < .01), with a similar difference seen in FTC133 cell lines (P < .0001). In vivo and biodistribution studies showed uptake of [89Zr]Zr-TR1402 in thyroid-stimulating hormone receptor-expressing tumors, with a mean percentage of injected dose/g of 1.9 ± 0.4 at 3 days post-injection. CONCLUSION:
|
Authors | Grayson R Gimblet, Jason Whitt, Hailey A Houson, Diana Lin, Rachael Guenter, Tejeshwar C Rao, Dezhi Wang, John Ness, Manuel Lora Gonzalez, Madisen S Murphy, Andrea Gillis, Herbert Chen, John A Copland, Saad S Kenderian, Ricardo V Lloyd, Mariusz W Szkudlinski, Suzanne E Lapi, Renata Jaskula-Sztul |
Journal | Surgery
(Surgery)
(Oct 31 2023)
ISSN: 1532-7361 [Electronic] United States |
PMID | 37919223
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Elsevier Inc. All rights reserved. |